

### Cognitive Challenges in Parkinson's and What to Do About Them!

Greg Pontone, MD, MHS Director, Parkinson's Neuropsychiatry Clinic Johns Hopkins University, School of Medicine

The Victory Summit<sup>®</sup> - Ottawa | October 5, 2019



## **Overview of cognitive impairment in Parkinson's**

The Victory Summit<sup>®</sup> - Ottawa | October 5, 2019



Mild Cognitive

### **Impairment in Parkinson's**

- Gradual decline in select cognitive abilities
- Deficits are not sufficient to interfere significantly with functional independence, but difficulties on complex tasks may be present





### Severe Cognitive Impairment in Parkinson's

- Impairment in two or more cognitive domains
- Decline from baseline with deficits that impair daily function



### **Cognitive functions/domains**

- **Executive** organization, planning, multitasking
- **Processing speed** how rapidly information is processed
- Attention ability to focus on a task or thought
- **Memory** ability to store and retrieve new information
- Visuospatial conception of spatial relationships
- **Language** ability to comprehend and express meaning, usually in words



### Impact of cognitive impairment on daily function

- Memory loss
- Difficulty performing familiar tasks
- Language deficits
- Time and place disorientation
- Poor judgment



### **Executive dysfunction and slowed mental processing speed**

- Deficits in initiation, sequencing, planning and set shifting; impaired mental speed (bradyphrenia)
- Often the earliest detectible cognitive changes in Parkinson's

### Attention/Executive dysfunction/processing speed – Influence of task demands in Parkinson's



every victory counts .

"Let's have tea!" study (Rochester et al, Arch Phys Med Rehab, 2004)

• Looked at how attentional demands during an everyday functional activity contributes to functional performance and gait disturbances

### Study • 20 mild to moderate people with Parkinson's, 10 controls

dysfunction/processing speed -

**Influence of task demands in Parkinson's** 

• Four Tasks

**Attention/Executive** 

- Simple walking: walk to the kitchen
- Dual-motor: walk and carry a tray
- Dual-cognitive: walk and recall a memory
- Multiple motor-cognitive task: walk, carry tray and recall a memory

#### Results

- Increased task complexity  $\rightarrow \downarrow$  gait speed



every victory counts.



### Parkinson's and subcortical cognitive impairment

- Early pronounced executive dysfunction, attentional deficits and slowed processing speed
- Language and memory are usually largely intact compared to cortical dementias until later in Parkinson's progression
- Deviation from this pattern, e.g., 'cortical' deficits could indicate comorbidity e.g., Alzheimer's disease, cerebral vascular disease or Lewy bodies in the cortex



### File Cabinet Example



The Victory Summit<sup>®</sup> – Ottawa | October 5, 2019

Memory Impairment Parkinson's vs. Alzheimer's: retrieval vs. encoding



every victory counts.

# **Encoding** = process of putting info into memory

## **Retrieval** = process of finding the info to remember

Memory Impairment Parkinson's vs. Alzheimer's: retrieval vs. encoding

Parkinson's memory impairment = poor retrieval

Alzheimer's memory impairment = impaired encoding

	Alzheimer's	Parkinson's
Recognition memory	<b>44</b>	-
Free recall memory	<b>44</b>	$\bullet$
Benefit for cueing	no	yes



every victory counts .



## **Evidence based treatments** for cognitive issues in Parkinson's

The Victory Summit<sup>®</sup> - Ottawa | October 5, 2019



## Treatments for mild (non-dementia) cognitive impairment in Parkinson's

Drug	Efficacy	Safety	<b>Practice implications</b>
Rivastigmine	Insufficient evidence	Acceptable risk without specialized monitoring	Investigational
Rasagiline	Insufficient evidence	Acceptable risk without specialized monitoring	Investigational
Transcranial direct current stimulation	Insufficient evidence	Insufficient evidence	Investigational
Cognitive rehabilitation	Insufficient evidence	Insufficient evidence	Investigational



## The Holy Grail – Disease modifying treatments







The Victory Summit<sup>®</sup> – Ottawa | October 5, 2019



#### Treatments for severe cognitive impairment (dementia) in Parkinson's

Drug	Efficacy	Safety	<b>Practice implications</b>
Rivastigmine	Efficacious	Acceptable risk without specialized monitoring	Clinically useful
Donepezil	Insufficient evidence	Acceptable risk without specialized monitoring	Possibly useful
Galantamine	Insufficient evidence	Acceptable risk without specialized monitoring	Possibly useful
Memantine	Insufficient evidence	Acceptable risk without specialized monitoring	Investigational



## Action Items: what you can do to help cognitive function

The Victory Summit<sup>®</sup> - Ottawa | October 5, 2019



### **Action items**

- Reduce distractions
- Focus on one task at a time
- Talk to your doctor about depression
- Exercise
- Quality sleep
- Healthy diet
- Cognitive training/rehabilitation
- Social interaction



### **Overview of psychosis in Parkinson's**

The Victory Summit<sup>®</sup> - Ottawa | October 5, 2019



Psychosis – a general definition

"A severe mental disorder in which contact is lost with external reality"



The Victory Summit<sup>®</sup> – Ottawa | October 5, 2019



### **Psychosis – definitions**

- Hallucinations false sensory perceptions in the absence of external stimuli
- **Illusions** misperception of actual stimuli
- **Passage hallucinations** indefinite object passing through the peripheral visual field
- Sense of presence hallucination a 'feeling' (or idea) of someone close by (leibhatige Bewussheit from Jaspers)
- **Delusions** false, fixed, idiosyncratic belief



### Parkinson's disease psychosis (PDP) typically occurs in more advanced stages of Parkinson's



The Victory Summit<sup>®</sup> – Ottawa | October 5, 2019



## **Evidence based treatments** for psychosis in Parkinson's

The Victory Summit<sup>®</sup> - Ottawa | October 5, 2019



### **Management Strategies**

- Treatment of underlying medical illness, if needed
- Discontinuation of medications that may exacerbate psychosis (eg, pain, bladder and CNS-acting medications)
- Reduction of Parkinson's medications
- Use of antipsychotic therapy
- Treatment with cholinesterase inhibitors
- Nonpharmacologic techniques to address PDP

### Antipsychotic Treatments for Parkinson's disease psychosis



every victory counts .

Trea	atment	Efficacy	Safety	Practice Implications
MDS review designation (2019) <sup>1</sup>	Clozapine	Efficacious	Acceptable risk with specialized monitoring	Clinically useful†
	Quetiapine	Insufficient evidence	Acceptable risk without specialized monitoring	Possibly useful†
FDA approved for PDP (2016) <sup>2</sup>	Pimavanserin	Efficacious <sup>3</sup>	No impairment of motor function <sup>3</sup> ; increase in QT interval	Clinically useful

<sup>†</sup> Black box warning for typical and atypical APs in elderly patients who have dementia-related psychosis<sup>4</sup>

1. Seppi K, et al. Mov Disord. 2019;34:2 2. US Food and Drug Administration Web site.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm498442.htm. Published April 29, 2016. Accessed October 27, 2016. **3.** Cummings J, et al. *Lancet*. 2014;383(9916):533-540. **4.** US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ucm124830.htm. Published June 16, 2008. Accessed November 5, 2016.

#### The Victory Summit<sup>®</sup> – Ottawa | October 5, 2019



## Action Items: what you can do for psychosis in Parkinson's

The Victory Summit<sup>®</sup> - Ottawa | October 5, 2019



#### Action items - Strategies for psychosis in Parkinson's Talk to your doctor!

- Home modifications (e.g. night lights), stimulation/structured environment
- Coping strategies

   -visual techniques
   -cognitive techniques
   -interactive techniques

  Discussion, education



### **Selected References**

Calleo, J., Burrows, C., Levin, H., Marsh, L., Lai, E., & York, M. K. (2012). Cognitive rehabilitation for executive dysfunction in Parkinson's disease: application and current directions. *Parkinson's Disease*, 2012.

Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017 Feb;13(2):81–95.

Goldman, J. G., Vernaleo, B. A., Camicioli, R., Dahodwala, N., Dobkin, R. D., Ellis, T., ... & Golden, R. (2018). Cognitive impairment in Parkinson's disease: A report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health. *npj Parkinson's Disease*, 4(1), 19.

Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011 Aug 15;26(10):1814–24.

Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of parkinson's diseasean evidence-based medicine review. *Mov Disord*. 2019;34(2):180-198.